Journals / Medical Network Klinik Bilimler ve Doktor / 2003 / Cilt: 9 - Sayı: 5

The effects of HMG-CoA reductase inhibitors on lomber vertebral bone mineral density in postmenopausal, type II diabetic, hyperlipidemic subjects

Postmenopozal, tip II diabetik, hiperlipidemik olgularda HMG-CoA redüktaz inhibitörlerinin lomber vertebra kemik mineral dansitesi üzerine etkileri

Pages
539–544
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In this study fluvastatin+alphacalcidol treatment was found to be more affective than alphacalcidol ; treatment alone in postmenopausal osteoporosis and it may be postulated that the statins can take place in combination treatment modalities for osteoporosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate and compare the effects of one year alphacalcidol and alphacalcidol+fluvastatin treatments on the lumbar vertebral bone mineral density in postmenopausal osteopenic or osteoporotic, type Il diabetic, hyperlipidemic subjects.
📊
Key Findings & Data:Material and Method: Postmenopausal osteopenic or osteoporotic, type Il diabetic, hyperlipidemic 42 female patients with mean age 55.8±3.6 were recruited for the study.
💡
Conclusion & Impact:Conclusion: In this study fluvastatin+alphacalcidol treatment was found to be more affective than alphacalcidol ; treatment alone in postmenopausal osteoporosis and it may be postulated that the statins can take place in combination treatment modalities for osteoporosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kemik yoğunluğu · Osteoporoz · postmenopozal

Abstract

Objective: To evaluate and compare the effects of one year alphacalcidol and alphacalcidol+fluvastatin treatments on the lumbar vertebral bone mineral density in postmenopausal osteopenic or osteoporotic, type Il diabetic, hyperlipidemic subjects. Material and Method: Postmenopausal osteopenic or osteoporotic, type Il diabetic, hyperlipidemic 42 female patients with mean age 55.8±3.6 were recruited for the study. All subjects were taking oral antidiabetic drugs for diabetes, but were not taking any medication that would affect bone metabolism or hyperlipidemia. Subjects were randomly assigned into two groups, it was planned to give one year alphacalcidol treatment to the group I and alphacalcidol+fluvastatin treatment to the group II. All subjects' diabetes and menopause durations were evaluated, body mass indexes were calculated. Serum fasting blood glucose, HbA1C, calcium, phosphorus, ALP, 25 (OH) D3 levels and 24-hour calcium excretion in the urine were measured. All subjects' lumbar vertebral bone mineral density were evaluated with the dual energy x-ray absorbtiometry before and after the treatment. Results: There were no significant differences in the age, body mass index, diabetes and menopause durations bet-ween two groups. Also there were no differences in the biochemical parameters except serum triglycéride levels, that ;were significantly higher in the group II. There was no significant change in the lumbar vertebral bone mineral density ; after one year treatment in group I, but increase in the bone mineral density in group Il was statistically significant. Conclusion: In this study fluvastatin+alphacalcidol treatment was found to be more affective than alphacalcidol ; treatment alone in postmenopausal osteoporosis and it may be postulated that the statins can take place in combination treatment modalities for osteoporosis.

Özet

Amaç: Postmenopozal osteopenik veya osteoporotik, tip II diabetik, hiperlipidemik olgularda, bir yıllık alfakalsidol ile alfakalsidol+fluvastatin tedavilerinin lomber vertebra kemik mineral dansite üzerine etkilerini değerlendirmek ve karşılaştırmak. Gereç ve Yöntem: Çalışmaya, yaş ortalaması 55.8±3.6 olan 42 postmenopozal osteopenik veya osteoporotik, tip II diabetik, hiperlipidemik kadın hasta alındı. Tüm olgular diabete yönelik oral antidiabetik kullanıyorlardı. Ancak osteoporoza veya hiperlipidemiye yönelik ya da kemik metabolizmasını etkileyebilecek tedavi almıyorlardı. Çalışmaya alınan olgular iki gruba ayrıldı: I..gruba bir yıl boyunca alfakalsidol, II.gruba alfakalsidol+fluvastatin verilmesi planlandı. Tüm olguların diabet ve menopoz süreleri değerlendirildi, vücut kitle indeksleri hesaplandı. Serum AKS, HbA1C, kalsiyum, fosfor, ALP, 25 (OH) D3 düzeyleri ve 24 saatlik idrarda kalsiyum düzeyi ölçüldü. Tüm olguların te-daviden önce ve sonra lomber vertebra kemik mineral dansiteleri dual enerji x-ray absorbsiometri ile değerlendirildi. Bulgular: Her iki grup arasında yaş, vücut kitle indeksi, diabet ve menopoz süreleri açısından anlamlı farklılık yoktu. Biyokimyasal parametrelerden, sadece serum trigliserid düzeyi II. grupta anlamlı olarak daha yüksekti. Ancak diğer parametreler açısından istatistiksel olarak anlamlı farklılık yoktu. I. grupta bir yıllık tedavi sonrasında lomber vertebra kemik mineral dansitesinde anlamlı değişiklik izlenmedi, II. grupta ise kemik mineral dansitede istatistiksel olarak anlamlı bir artış izlendi. Sonuç: Bu çalışmada postmenopozal osteoporozda fluvastatin+alfakalsidol tedavisi, tek başına alfakalsidol tedavisinden daha etkili bulunmuştur ve statinlerin, osteoporozda uygulanan kombinasyon tedavileri arasında yer alabileceği ileri sürülebilir.

🔖

Cite This Article

YILMAZ, H., YILDIZ, M., HEKİMOĞLU, B., ÖMEROĞLU, E., CERAN, F., BOYDAK, A., ILIMAN, N., İNAM, F. U. (2003). The effects of HMG-CoA reductase inhibitors on lomber vertebral bone mineral density in postmenopausal, type II diabetic, hyperlipidemic subjects. Medical Network Klinik Bilimler ve Doktor, Cilt: 9 - Sayı: 5, 539–544. https://ajindex.com/articles/278508

References (12)

  1. Gökçe-Kutsal Y. Osteoporoz. İn: Beyazova M, Gökçe-Kutsal Y, editors. Fiziksel Tıp ve Rehabilitasyon. Güneş Kitabevi Ltd. Şti, 2000:1872-93.
  2. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone mineral density in postmenopausal women. Lancet 2000; 355:2218-9.
  3. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation, in vitro and in rodents by statins. Science 1999; 286:1946-9.
  4. Edwards CJ, Russel RG, Spector TD. Statins and Bone: Myth or reality? Calcif Tissue Int 2001; 69:63-6. Edwards JC. Statins and bone morphogenetic proteins: new pathways in bone formation. Ann Acad Med Singapore 2002; 31:245-7. Lopez FJ. New approaches to the treatment of osteoporosis. Curr Opin Chem Biol. 2000; 4:383-93. Whitfield JF. Statins: new drugs for treating osteoporosis. Expert Opin Invest Drugs 2001; 10:409-15.
  5. Van Beek E, Lowik C, Plujim G, Papapoulos S. The role of geranylgeranylation in bone resorbtion and its suppression by bisphosponates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosponates. Journal of bone and mineral research 1999; 14:722-9.
  6. Chung Y, Lee SK, Kim H, Fitzpatrick LA. HMG-CoA reductase inhibitors increase BMD in type II diabetes mellitus patients. The J Clin Endocrin and Metabolism 2000; 85:1137-42.
  7. Wada Y, Nakamura Y, Koshiyama H. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type II diabetes. Arch Intern Med 2000; 160:2865-6.
  8. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T. Effects of 1-year treatment with fluvastatin or pravastatin on bone. The Am Journal of Med 2001; 110:584-7.
  9. Piepkom B, Kann P, Forst T, Andreas J, Pfützner A, Beyer J. Bone mineral density and bone metabolism in diabetes mellitus. Horm Metab Res. 1997; 29:584-91.
  10. Tuominen J, Puukka P, Imprivaara O, Rönnemaa T. Bone mineral density in patients with type I and type II diabetes. Diabetes Care 1999; 22:1196-200.
  11. Kemink SAG, Hermus A, Swinkels LM, Lutterman JA, Smals AGH. Osteopenia in insulin-dependent diabetes mellitus: preva­lence and aspects of pathophysiology. J Endocrinol Invest. 2000; 23:295-303.
  12. Leidig-Bruckner G, Ziegler R. Diabetes mellitus: a risk for osteoporosis? Exp Clin Endocrinol Diabetes 2001; 109(suppl): 493-514. Kumbasar B. Diabetes mellitusta kemik ve eklem bozukluk­ ları, osteoporoz. İn: Yenigün M ed. Her Yönüyle Diabetes Mellitus, 2.baskı, Nobel Tıp Kitabevi Ltd Şti 2001:623. Isaia GC, Ardissone P, Stefano MD, et al. Bone meta